CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 5, 2006--Idera Pharmaceuticals (AMEX: IDP - News) today announced that it had presented preclinical data for its TLR9 agonists in mouse lung cancer models at the American Society of Clinical Oncology (ASCO) Annual Meeting. These data demonstrate that in the preclinical studies conducted by Idera, Idera’s TLR9 agonists enhanced the antitumor effect of several common chemotherapeutic agents including Gemzar® and Alimta® and the targeted cancer therapy Tarceva®, and also had monotherapy activity. The new observations with Tarceva add to previous preclinical data developed by Idera collaborators of synergistic activity between Idera’s TLR9 agonists and other EGFR inhibitors. Idera’s lead TLR9 agonist IMO-2055 is currently in Phase 2 and Phase 1/2 clinical trials for renal cell carcinoma and for non-small cell lung cancer, respectively.
